Health
Shorter Duration of Adjuvant Trastuzumab Shows Long-Term Survival Benefit in Select HER2+ Early Breast Cancer – OncLive
Although administering trastuzumab for 1 year in patients with HER2-positive early breast cancer continues to be standard, a 9-week de-escalation approach may be…
Updated survival data from the phase 3 Short-HER trial (NCT00629278) presented during the ESMO Breast Cancer Virtual Congress 2021confirm the promising long-term results obtained with 9 weeks of adjuvant trastuzumab (Herceptin) in patients with HER2-positive early breast cancer who have low and intermediate risk factors, a population that is representative of most patients seen in clinical practice.1After a median follow-up of 8.7 years, patients who received 1 year of trastuzumab had a 5-year disease-free…
-
Business19 hours agoThe pros and cons of buying CBA shares in September
-
Noosa News19 hours agoRent changes on way for hundreds of social housing recipients following government review
-
Noosa News18 hours agoPolice reject claims about detained protester; SEQ train lines to be disrupted; BlueCare to cut enrolled nurses
-
Business15 hours agoWhere will Berkshire Hathaway be in 1 year?